Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial,
comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel
+cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a
humanized anti-PD1 IgG4 monoclonal antibody.